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Viruses are obligate intracellular parasites and are some of the most rapidly evolving and diverse patho-
gens encountered by the host immune system. Large complicated viruses, such as poxviruses, have
evolved a plethora of proteins to disrupt host immune signalling in their battle against immune surveil-
lance. Recent X-ray crystallographic analysis of these viral immunomodulators has helped form an
emerging picture of the molecular details of virus-host interactions. In this review we consider some
of these immune evasion strategies as they apply to poxviruses, from a structural perspective, with spe-
ciﬁc examples from the European SPINE2-Complexes initiative. Structures of poxvirus immunomodula-
tors reveal the capacity of viruses to mimic and compete against the host immune system, using a
diverse range of structural folds that are unique or acquired from their hosts with both enhanced and
unexpectedly divergent functions.
 2011 Elsevier Inc. Open access under CC BY license.1. Introduction
Vaccinia virus (VACV), the smallpox vaccine, is the prototype
member of the Orthopoxvirus genus of the Poxviridae: a family of
large, complex dsDNA viruses that replicate in the cytoplasm of
host cells and form virions with a unique morphology (Condit
et al., 2006; Moss, 2007). The VACV genome reﬂects the complexity
of poxviruses in both gene composition and structure. Its linearwpox virus; dsDNA, double-
osaminoglycans; GPCRs, G-
oglobulin; PDB, protein data
e deviation; SPINE, Structural
umour necrosis factor; TNFR,
s; vCCI, viral CC-chemokine
actor 2 alpha; TRAF6, TNF-
associated kinases; IKK, IjB
rt), jonathan@strubi.ox.ac.uk
Research and Department of
brooke’s Hospital, Hills Road,
UK Gurdon Institute, Univer-
1QN, United Kingdom.
nstitute of Child Health, 30
 license.dsDNA genome ranges from 185–200 kbp in size, with a capacity
to encode around 200 distinct proteins (Lefkowitz et al., 2006;
Moss, 2007). The highly conserved central portion of most poxvirus
genomes contains essential genes involved in key functions such as
transcription, DNA replication and virion assembly. In contrast,
genes that cluster at the ends of the genome are usually species-
or host-speciﬁc and encode virulence factors that modulate the
host immune system (Gubser et al., 2004; Jackson et al., 2005).
Analysis of poxvirus genomes has shed new light on poxvirus phy-
logeny and evolution (Lefkowitz et al., 2006) showing that poxvi-
rus proteins are generally more similar to eukaryotic proteins
than bacterial, suggesting that gene acquisition by horizontal gene
transfer from their eukaryotic hosts has been a slow but ongoing
process that has contributed to the evolution of poxviruses (Espos-
ito et al., 2006; Lefkowitz et al., 2006). Many of these host-derived
genes facilitate poxvirus immune evasion. VACV immunomodula-
tors function both outside and inside infected host cells. Proteins
that are secreted from infected cells are directed toward binding
and disrupting the function of complement, interferons (IFNs),
cytokines and chemokines (Alcami, 2003; Alcami and Koszinowski,
2000; McFadden and Murphy, 2000; Perdiguero and Esteban,
2009), as well as semaphorin signalling (Seet et al., 2003). Con-
versely, intracellular immunomodulators modulate apoptosis, the
antiviral effects of IFNs, innate immune signalling and host gene
transcription (Haga and Bowie, 2005; Perdiguero and Esteban,
2009; Seet et al., 2003; Taylor and Barry, 2006).
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poxvirus immunomodulators (summarised in Table 1), focussing
on what we have learnt from the ﬁve speciﬁc examples of extra-
and intracellular immune modulators of VACV that have been
solved as part of SPINE2-Complexes (shown in their functional
context in Fig. 1). We highlight how VACV has evolved to use
two broad classes of immunomodulators: those acquired from
the host and those that appear to have no relationship to known
host proteins. This work emphasises how poxviruses are able to ac-
quire and replicate a number of structural scaffolds to carry out re-
lated but distinct immunomodulatory functions and underscores
the observation that apparently unrelated sequences have often di-
verged from host acquired genes whilst conserving structure.
2. Extracellular immune evasion
Two structures of secreted VACV proteins that inhibit cytokines
and chemokines were determined as part of the SPINE2-complexes
activity and a number of structures have been determined by oth-
ers, which are summarised ﬁrst (Table 1). The crystal structure of
the complex between ectromelia virus (ECTV) interleukin (IL)-18
binding protein and human IL-18 (Krumm et al., 2008) reveals that
the viral protein has a canonical immunoglobulin (IG)-like fold and
functions by blocking a putative receptor binding site on IL-18
(Krumm et al., 2008). The ECTV IFN-c binding protein (IFN-cBP)
complexed with IFN-c also reveals a conservation of structure with
the extracellular domain of the host IFN-c receptor (Nuara et al.,
2008). Furthermore, in this complex it was shown that ECTV IFN-
cBP forms secreted tetramers that sequester two dimers of host
IFN-c. Oligomerisation of ECTV IFN-cBP is achieved through a he-
lix-turn-helix motif that is similar in structure to the transcription
factor TFIIA, demonstrating poxvirus acquisition of structural folds
that have been adapted for additional functions by immunomodu-
lators (Nuara et al., 2008). Lastly, recent structures of the VACV se-
creted protein A39 have provided mechanistic information about
viral inhibition of semaphorins, a family of conserved signalling
molecules that play crucial roles in the development of the nervous
system and in immune regulation, through interactions at the cell
surface with their cognate plexin receptors (Suzuki et al., 2008).
VACV A39 is a secreted poxviral homolog of sema7A, and the crys-
tal structure of the A39-PlexinC1 complex conﬁrms that viral sem-
aphorins share a conserved binding mode – adapted for higher
afﬁnity – to host semaphorin-plexin interactions (Liu et al., 2010,Table 1
Structures of poxvirus immunomodulators present in the PDB.
Description
Extracellular immunomodulators
A41 Chemokine inhibitor
CPXV vCCI Chemokine inhibitor
Rabbitpox virus vCCI Chemokine inhibitor (complex)
ECTV vCCI Chemokine inhibitor
CrmE TNF-a inhibitor
TPXV 2 MHC-like TNF-a inhibitor
IL-18 BP Blocks IL-18 binding to IL-18R
IFN-gamma BP Blocks IFNc - binding to IFN-cR
A39 Semaphorin 7A mimic
Intracellular immunomodulators
N1 Bcl-2–like inhibitor of apoptosis and toll-like receptor sign
B14 Bcl-2–like inhibitor of NF-jB
A52 Bcl-2–like inhibitor of NF-jB
K7 Bcl-2–like inhibitor of NF-jB and IFN-b
F1 Bcl-2–like anti-apoptotic
M11 Bcl-2–like anti-apoptotic
K3 Inhibits PKR mediated phosphorylation of eIF2a
VH1 Dephosphorylates STAT-1, blocks expression of IFN induce
Structures highlighted in bold were determined as part of SPINE2-Complexes.and see Bowden et al. in this issue). In each of these examples
the relationship between the virus protein and its cellular counter-
part(s) was deduced from comparison of primary amino acid se-
quence and prompted speciﬁc experiments to test function.
However, in some other examples below, no such primary se-
quence similarity was evident and protein structure provided
inference about possible function.
2.1. Poxvirus inhibition of TNFa – CrmE and Tanapoxvirus protein 2
Tumour necrosis factor a (TNFa) is the prototypic member of a
superfamily of potent pro-inﬂammatory cytokines that can induce
an anti-viral state and promote apoptosis in virus-infected cells
(Aggarwal, 2003; Locksley et al., 2001). Poxviruses have countered
the selection pressure of the TNF superfamily by evolving proteins
that disrupt TNFa-induced apoptosis (Alcami, 2003; Taylor and
Barry, 2006). Two distinct classes of secreted poxvirus TNFa-bind-
ing proteins have now been characterised structurally (Table 1):
those that share sequence similarity to the extracellular domain
of cognate host TNF receptors (TNFRs) (Cunnion, 1999; Saraiva
and Alcami, 2001) and, more recently, a separate protein that
resembles the mammalian MHC class I heavy chain (Brunetti
et al., 2003). The structure of VACV cytokine response modiﬁer E
(CrmE), solved as part of SPINE2-Complexes, was the ﬁrst crystal
structure of a virus-encoded TNFR (Graham et al., 2007). CrmE
shares sequence identity (30%) with the human TNFR superfamily
proteins 1A (TNFRSF1A), and the structure of CrmE (Figs. 1 and 2)
adopts the canonical fold of the TNFR family of proteins, compris-
ing three cysteine-rich domains (CRDs 1–3). Each CRD contains
three intra-domain disulphide bonds (Fig. 2). The structure of CrmE
has shown that only one of the two ligand-binding loops present in
human TNF receptors are conserved in this viral counterpart. This
has provided a structural basis for understanding the higher afﬁn-
ities of poxvirus TNFRs for the cytokine TNFa over other cytokines
such as lymphotoxin-a (Graham et al., 2007), which is supported
by the recent structure of TNFR2 in complex with TNFa (Mukai
et al., 2010). In contrast to VACV CrmE, the TPXV protein 2 binds
TNFa to inhibit host antiviral responses yet does not share se-
quence similarity to host TNFRs (Brunetti et al., 2003). The recent
structure of a TPXV 2-TNFa complex has revealed that the TPXV
protein 2 adopts an MHC class I structural fold but lacks a peptide
binding groove for antigen presentation (Yang et al., 2009). The
high-afﬁnity binding between TPXV protein 2 and TNFa (BrunettiReferences PDB ID
Bahar et al. (2008) 2VGA
Carﬁ et al. (1999) 1CQ3
Zhang et al. (2006) 2FIN
Arnold and Fremont (2006) 2GRK
Graham et al. (2007) 2UWI
Yang et al. (2009) 3IT8
Krumm et al. (2008) 3F62
Nuara et al. (2008) 3BES
Liu et al. (2010) 3NVX
alling to NF-jB Cooray et al. (2007); Aoyagi et al. (2007) 2UXE 2I39
Graham et al. (2008) 2VVY
Graham et al. (2008) 2VVW
Oda et al. (2009) 3JRV
Kvansakul et al. (2008) 2VTY
Kvansakul et al. (2007) 2JBY
Dar and Sicheri (2002) 1LUZ
d genes (ISGs) Koksal et al. (2009) 3CM3
Fig.1. Schematic cartoon highlighting some of the anti-viral immune signalling pathways targeted by VACV. Structures of VACV proteins solved by work funded in part by
SPINE2-Complexes are shown as cartoons, coloured from blue (N terminus) to red (C terminus), along with the points where they interfere with signalling.
M.W. Bahar et al. / Journal of Structural Biology 175 (2011) 127–134 129et al., 2003) is explained structurally by similarities in the TNF
binding sites on TPXV protein 2 and host TNFRs despite different
structural folds. The structure of both CrmE and TPXV 2 demon-
strate modiﬁcation of host structural folds to confer adapted spec-
iﬁcities for the host TNFa ligand.
2.2. Poxvirus inhibition of chemokine signalling – A41 and other vCCIs
Chemokines are secreted proteins (classiﬁed into C, CC, CXC and
CX3C subfamilies) that bind cell surface GAGs to form concentra-
tion gradients on vascular endothelial cell surfaces that direct the
migration of leukocytes into areas of infection and inﬂammation
(Charo and Ransohoff, 2006; Rot and von Andrian, 2004; Zlotnik
and Yoshie, 2000). Several poxviruses encode a secreted viral CC
chemokine inhibitor (vCCI) that prevents the interaction of chemo-
kines with their host receptors on leukocytes.
Structures of vCCI proteins from cowpox virus (CPXV) (Carﬁ
et al., 1999), rabbitpox virus (RPXV) (Zhang et al., 2006) and ECTV
(Arnold and Fremont, 2006) (Table 1) reveal a distinct b sandwich
topology with no obvious relationship to host chemokine recep-
tors, which are seven-transmembrane G-protein coupled receptors
(GPCRs). The vCCI b sandwich exposes two b sheets; sheet I is ﬂat
and electrostatically bland, whereas the second face (sheet II) pro-jects an elaborate conserved loop that forms a negatively-charged
surface. The acidic surface residues of sheet II are highly conserved
in vCCI proteins and the structure of the complex between RPXV
vCCI and human CCL4 has shown that these residues are the che-
mokine-binding surface for vCCI proteins (Zhang et al., 2006). Fur-
thermore, structure-based mutational analysis of the ECTV vCCI
protein highlighted residues involved in high afﬁnity interactions
between vCCIs and their CC chemokine partners (Arnold and Fre-
mont, 2006).
The VACV A41 protein (studied as part of SPINE2-complexes) is
secreted from infected cells, affects the host response to infection
and has limited sequence similarity to CPXV and ECTV vCCIs
(20% identity) (Clark et al., 2006; Ng et al., 2001). The 1.9 Å crystal
structure of VACV A41 shows considerable similarity to vCCI pro-
teins from other poxviruses (Bahar et al., 2008) (Figs. 1 and 2).
The core b sandwich topology is conserved (2.4 Å r.m.s.d for 159
matching Ca atoms between A41 and CPXV), as are the disul-
phide-forming cysteine residues present in A41 and vCCIs. The
most notable deviation between the structures of vCCIs and A41
lies in the topology of b sheet II (Fig. 2). CPXV vCCI contains an ex-
tended and highly acidic loop (the 2–4 loop) between b strands 2–4
that contributes signiﬁcant negative charge to b sheet II (Carﬁ
et al., 1999). This loop is conserved in both the RPXV (Zhang
Fig.2. Extracellular VACV immunomodulators CrmE and A41 inhibit TNFa and CC
chemokines respectively. (A) The structure of CrmE. In the left panel CrmE is shown
colour ramped from blue (N terminus) to red (C terminus), and in the right panel
the domain structure of CrmE is shown in a ribbon representation with CRDs 1–3
coloured blue, green and red, respectively. (B) The structure of A41 (pale green) is
shown superposed onto the vCCI of cowpox virus (CPXV, wheat) with conserved b
strands forming the b sheets labelled. The view in the right panel is rotated 90with
respect to the left panel and the ‘2–4 loop’ present in vCCI’s is highlighted red and
labelled.
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but is absent in A41. In the solution structure of the complex be-
tween RPXV and the CC chemokine CCL4 the 2–4 loop forms a
binding site for the chemokine through electrostatic interactions
(Zhang et al., 2006).
Functional results demonstrate that A41 binds a small subset of
CC chemokines (CCL21, 25, 26 and 28) with an afﬁnity that is 1–3
orders of magnitude lower (nM) than that of vCCI proteins for a
wide range of CC chemokines (pM) (Bahar et al., 2008; Ruiz-Argu-
ello et al., 2008). Consequently, A41 does not disrupt the high afﬁn-
ity interactions of chemokines with their cellular receptors and is
unable to inhibit leukocyte chemotaxis in response to these che-
mokines (Bahar et al., 2008). High concentrations of GAGs such
as heparin and dextran sulphate disrupt the A41-chemokine inter-
action suggesting that A41 functions by binding chemokines on
their GAG binding site rather than their receptor binding site.
The absence of the 2–4 loop in the structure of A41 is notable, since
it may help explain the selectivity of A41 for only a subset of che-
mokines, and modelling of A41-chemokine binding suggests that
the interaction is otherwise similar to that seen between vCCIs
and their chemokine partners (Bahar et al., 2008). Structures of
A41 and other poxvirus vCCIs have shown that poxviruses have
modiﬁed a single core structural fold to comprehensively block
separate aspects of chemokine-induced inﬂammatory responses;
high afﬁnity (pM) chemokine interactions with their receptors
are blocked by vCCIs and lower afﬁnity (nM) chemokine–GAG
interactions are inhibited by A41 disrupting chemokine gradients.3. Intracellular immune evasion
In contrast to extracellular immunomodulators, poxvirus inhi-
bition of intracellular immune signalling targets not only the
downstream signalling events from cytokines such as TNFa and
IFNc, but more prominently exerts control over apoptosis; the pro-
grammed form of cell death that eradicates damaged or pathogen-infected cells (Everett and McFadden, 2002; Taylor and Barry,
2006). Three structures of intracellular signalling modulators have
been determined in the course of SPINE2-complexes and additional
structures have been determined by others (Table 1), and these are
considered ﬁrst.
Downstream IFN-signalling pathways activate the transcription
factor STAT1 (signal transducer and activator of transcription 1)
(Levy and Darnell, 2002), which induces the expression of impor-
tant antiviral genes (Krause and Pestka, 2007). VACV VH1 protein
is a dual speciﬁcity phosphatase that inhibits STAT1 by dephospho-
rylation (Mann et al., 2008; Najarro et al., 2001). The 1.3 Å crystal
structure of VACV VH1 reveals a homodimer assembly with a
prominent N-terminal helix domain swap that exposes two phos-
phatase active sites (Koksal et al., 2009). Functional work in the
same study also showed that VH1 dephosphorylates STAT1 in the
absence of bound DNA, suggesting that the VACV VH1 protein acts
on cytoplasmic pools of STAT1 prior to nuclear translocation (Kok-
sal et al., 2009). One of the genes induced in part by STAT1 is the
dsRNA-dependent protein kinase (PKR), which detects dsRNA pro-
duced during VACV transcription and in response phosphorylates
and inhibits the host protein translation factor eukaryotic transla-
tion initiation factor 2 alpha (eIF2a). This arrests synthesis of viral
and host proteins in infected cells, leading to apoptosis (Garcia
et al., 2006; Gil and Esteban, 2000). The VACV K3 protein is a viral
mimic of the N-terminal 88 amino acids of eIF2a and circumvents
PKR-induced apoptosis by binding to PKR and acting as a non-
phosphorylable pseudosubstrate of PKR (Beattie et al., 1991; Car-
roll et al., 1993). The structure of K3 consists of a ﬁve-stranded
b-barrel and mutational analysis of the structure reveals that two
separate regions of K3 are responsible for binding PKR and inhibit-
ing its phosphorylation of eIF2a (Dar and Sicheri, 2002).
Apoptosis represents an important host innate immune re-
sponse to infection and aids elimination of virus-infected cells
(Roulston et al., 1999). The B-cell lymphoma 2 (Bcl-2) family are
small a-helical proteins that are either pro- or anti-apoptotic, reg-
ulating the release of pro-apoptotic molecules from mitochondria
(Youle and Strasser, 2008). Unsurprisingly, several viruses, includ-
ing adenovirus and herpesvirus, express anti-apoptotic viral Bcl-2
proteins to evade cell death (Polster et al., 2004). Recent functional
and structural data has identiﬁed a family of poxviral proteins that
lack sequence similarity to cellular or viral Bcl-2 proteins yet adopt
a Bcl-2 fold and act as potent anti-apoptotic Bcl-2 proteins (Ta-
ble 1). Crystallographic analysis of these poxvirus Bcl-2–like pro-
teins has revealed details of viral inhibition of apoptosis and, for
speciﬁc examples from VACV, has also revealed unexpected adap-
tations of Bcl-2-folds for wider intracellular signal modulation, dis-
cussed below (Table 1).
3.1. Poxvirus Bcl-2–like proteins that block apoptosis – N1, M11 and
F1
In work performed as part of SPINE2-Complexes and by others,
the VACV N1 protein, a VACV virulence factor (Bartlett et al., 2002),
was shown to possess an a-helical fold very similar to cellular Bcl-
2 family members, despite lacking detectable sequence similarity
to Bcl-2 homology (BH) motifs (Fig. 3) (Aoyagi et al., 2007; Cooray
et al., 2007). Similar to host anti-apoptotic Bcl-2 proteins, N1 con-
tains conserved structural features including a prominent surface
groove, which in cellular Bcl-2 proteins binds BH3 motifs of pro-
apoptotic family members and inhibits their cell death functions
(Hinds and Day, 2005; Liu et al., 2003; Petros et al., 2004). In
cellular Bcl-2 proteins, access to the surface groove is modulated
by a C-terminal helix that is displaced from the groove before
pro-apoptotic Bcl-2 proteins can be sequestered (Hinds et al.,
2003; Wilson-Annan et al., 2003). In contrast, the N1 C-terminal
helix is truncated and the surface groove is constitutively open
Fig.3. VACV proteins A52, B14 and N1 share a Bcl-2–like fold. (A) A52, (B) B14 and (C) N1 are shown as ribbons, rainbow coloured from blue (N terminus) to red (C terminus).
The disulphide bond observed in B14 is shown as purple spheres. (D) Structure-based sequence alignment of the VACV Bcl-2–like proteins. Residues that are highly or
moderately conserved (BLOSUM62 score) are coloured marine and light blue, respectively, and cysteine residues that form the disulphide bond observed in B14 are boxed and
in purple face. The secondary structures of A52, B14 and N1 are shown above the sequences with a helices represented as cylinders. This ﬁgure is revised and updated from
Graham et al., 2008.
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BH3 motifs into the N1 surface groove reveals that, unlike the pre-
dominantly hydrophobic grooves of its cellular counterparts, the
N1 binding pocket displays some charged characteristics, suggest-
ing that although the core binding sites are conserved, N1 may
bind BH3 motifs selectively (Cooray et al., 2007). Functional work
conﬁrms that N1 inhibits apoptosis in VACV-infected cells, and that
N1 interacts with pro-apoptotic Bcl-2 proteins such as Bid, Bad,
Bak and Bax in vivo (Cooray et al., 2007) and in vitro (Aoyagi
et al., 2007). In addition, the N1 protein has been reported to inhi-
bit innate immune signalling pathways by binding to both the IKK
complex and TANK binding kinase 1 (TBK1) and thereby inhibit
activation of nuclear factor (NF)-jB and IRF3 (DiPerna et al., 2004).
Myxoma virus (MYXV) M11 and VACV F1 have also been iden-
tiﬁed as poxvirus proteins that inhibit apoptosis (Everett et al.,
2002; Fischer et al., 2006) and recent structures have conﬁrmed
they are viral Bcl-2 family proteins. The X-ray structure of the
MYXVM11 protein (Douglas et al., 2007; Kvansakul et al., 2007) re-
veals that, despite lacking sequence similarity to other Bcl-2 pro-
teins, it adopts an entirely a-helical fold similar to VACV N1 and
host Bcl-2 proteins. Fluorescence polarization assays have shown
that M11 binds BH3 peptides of pro-apoptotic Bak with a compa-
rable afﬁnity to some cellular Bcl-2 proteins (Douglas et al.,
2007) and the crystal structure of M11 in complex with the BH3
peptide of Bak conﬁrms a binding mode similar to cellular Bcl-2
members; the BH3 helix of Bak binding into the hydrophobic sur-
face groove of M11 (Kvansakul et al., 2007). The X-ray crystal
structure of VACV F1, reveals a conserved core Bcl-2 fold, but also
a novel domain-swapped mode of dimerisation, via an extended N-
terminal region, not observed in other host or viral Bcl-2 proteins
(Kvansakul et al., 2008). Previous binding data for F1 have shown
that F1 binds directly to the BH3 motifs of pro-apoptotic Bcl-2 pro-teins with afﬁnities ranging from 75 nM to over 1 lM (Fischer
et al., 2006). Unlike VACV N1, both M11 and F1 contain an ex-
tended C-terminal hydrophobic helix that localises them to the
mitochondrial membrane where they inhibit apoptosis (Everett
et al., 2002; Stewart et al., 2005). Host pro-apoptotic Bcl-2 proteins
such as Bak and Bax initiate apoptosis at the mitochondrial mem-
brane (Grifﬁths et al., 1999; Hsu and Youle, 1998), and the pres-
ence of poxviral Bcl-2 proteins with (M11 and F1) and without
(N1) membrane localising C-terminal helices suggest poxviruses
have targeted the Bcl-2 pathway at both the cytosolic and mito-
chondrial membrane levels.
3.2. Poxvirus Bcl-2–like proteins that inhibit NF-jB pathway – A52,
B14, N1 and K7
Nuclear factor (NF)-jB is a transcription factor complex that
plays a central role in stimulating innate and adaptive immune re-
sponses to infection. Receptors for the pro-inﬂammatory cytokines
IL-1 and TNFa activate signalling pathways leading to NF-jB acti-
vation (Hayden and Ghosh, 2008; Hayden et al., 2006), as do Toll-
like receptors (TLRs), which recognise pathogen associated molec-
ular patterns in, for example, viral (glyco)proteins and nucleic
acids (Akira et al., 2006; Kawai and Akira, 2007). NF-jB activation
downstream of the IL-1 receptor and TLRs requires TNF-receptor-
associated factor 6 (TRAF6) and IL-1 receptor associated kinases
(IRAKs), while activation downstream of the TNF receptor requires
TRAF2 (Akira et al., 2006; Hayden et al., 2006). These independent
downstream signalling pathways converge at the IjB kinase (IKK)
complex, a key regulator of signalling to NF-jB activation (Hayden
and Ghosh, 2008). The importance of the inﬂammatory immune
response initiated by NF-jB is underscored by the fact that VACV
encodes several proteins, A52, B14, N1, and K7, that inhibit aspects
Fig.4. Structure-based phylogenetic analysis of virus and cellular Bcl-2–like
proteins. The structures were superposed, pairwise distance matrix was con-
structed and tree drawn as described in (Graham et al., 2008). PDB codes for each
structure used are given followed by their species of origin in parentheses [Human
(H), Mouse (M), Rat (R), C. elegans (C), Vaccinia virus (VACV), Myxoma virus (MV),
Kaposi sarcoma herpes virus (KSHV), murine gamma-herpesvirus 68 (MHV),
Epstein-Barr virus (EBV)]. Although likely, it is not certain that all Bcl-2–like
proteins share a common ancestor and, as such, the root of the tree is shaded.
Ribbon diagrams of representative structures for each protein are rainbow coloured
from blue (N terminus) to red (C terminus).
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2003; Schroder et al., 2008; DiPerna et al., 2004). Members of this
group belong to a Pfam (Finn et al., 2008) protein family that also
includes A46, C6 and N2. Although these proteins have sequence
similarity permitting their grouping together, they do not share
signiﬁcant sequence similarity to other cellular or viral proteins
(Bowie et al., 2000; Smith et al., 1991).
Recent results from SPINE2-Complexes and others show that
VACV N1, A52, B14 and K7 are entirely a helical Bcl-2–like proteins
(Graham et al., 2008; Kalverda et al., 2009). The structures of A52
and B14 both comprise seven a helices (Fig. 3), and the closest
structural relative to both proteins is VACV N1 (Graham et al.,
2008). Functional work also demonstrates that unlike N1 and
MYXV M11, A52 and B14 do not inhibit mitochondrial apoptosis
(Graham et al., 2008). Superposition of A52 and B14 structures
onto MYXV M11 in complex with the BH3 peptide of Bak (Kvansa-
kul et al., 2007) reveals the hydrophobic BH3-peptide binding
grooves are occluded in both A52 and B14, but not in N1 (Fig. 3
and (Graham et al., 2008)), providing a molecular explanation for
the inability of A52 and B14 to protect cells from apoptotic chal-
lenge. The absence of a surface groove is also observed for VACV
K7, and consistent with this K7 does not inhibit apoptosis (Kal-
verda et al., 2009; Schroder et al., 2008). Functional work has also
established that B14 acts at the IKK complex to inhibit signalling to
NF-jB (Chen et al., 2008; Graham et al., 2008) whilst A52 blocks
signalling upstream of B14 by inhibiting TLR-induced signalling
through IRAK2 and TRAF6, consistent with previous observations
(Bowie et al., 2000; Harte et al., 2003). Like A52 and B14, VACV
K7 has a Bcl-2 fold (Kalverda et al., 2009) and, similar to A52, inhib-
its TLR-induced NF-jB activation (Schroder et al., 2008). However,
unlike A52 or B14, K7 also forms a complex with the human DEAD-
box RNA helicase DDX3 to antagonize IFN-b promoter induction
and inhibit the production of pro-inﬂammatory cytokines (Kal-
verda et al., 2009). The structure of K7 in complex with a peptide
of DDX3 visualised the molecular details of this interaction (Oda
et al., 2009) and reveals that the DDX3 peptide (representing the
N-terminal DDX3 residues 71–90) binds to a negatively charged
surface on K7 and buries two critical phenylalanine residues (F84
and F85) into a hydrophobic pocket on the surface of K7. Mutation
of these residues abolishes DDX3 binding to K7 and inhibits DDX3-
induced signalling, suggesting that VACV K7 sequesters DDX3 by
these critical motifs to inhibit IFN-b promoter induction. Collec-
tively, the structural results for VACV A52, B14 and K7 provide fur-
ther examples of poxviruses adapting host acquired structural
scaffolds and diversifying their functional repertoire.
3.3. The evolution of Poxvirus Bcl-2–like proteins
Intriguingly, the structures of N1, B14, A52, K7 and M11 suggest
that Bcl-2 proteins appear to be a good structural scaffold upon
which poxviruses have grafted a number of distinct immunomod-
ulatory functions. Using a structure based approach to phylogentic
analysis (Bamford et al., 2005) we have shown that viral Bcl-2 pro-
teins are more similar to each other than to cellular Bcl-2 proteins,
whilst for the cellular Bcl-2–like proteins, orthologues cluster to-
gether, residing closer to each other on the tree than to paralogue
structures from the same species (Graham et al., 2008) (Fig. 4). The
clustering of the Bcl-2 proteins of poxviruses and herpesviruses,
which are not thought to be related, may be due to an ancient hor-
izontal gene transfer event, since the Bcl-2 proteins from gamma-
herpesvirus 68 (cHV68) and Kaposi-sarcoma herpesvirus (KSHV)
diverge prior to the poxvirus proteins whilst the VACV and MYXV
proteins largely cluster together. In addition, the analysis reveals
that A52, B14, N1 and K7 are more closely related to each other
than they are to any other Bcl-2 family member, despite playing
distinct functional roles. This suggests that an ancestral poxvirusacquired a Bcl-2 family gene from the host and that gene duplica-
tion events during poxviruses evolution gave rise to structurally-
related proteins that have evolved separate and diverse functions,
as observed in the case of VACV N1, B14, A52, K7 and M11 of myx-
oma virus. Furthermore N1, which has both anti-apoptotic and
anti-signalling functions, occupies an intermediate position on
the tree, branching after M11 (which is only anti-apoptotic with
an open peptide binding groove) and before B14, K7 and A52
(which are only anti-signalling and possess occluded grooves).4. Concluding remarks
Until recently, the structural biology of viral immune evasion
proteins had progressed slowly compared to their functional and
biochemical characterisation. However, a steady increase in struc-
tural data is now being achieved, and the ability of structural com-
parison to detect distant relationships has revealed that whilst
viral immunomodulators have been placed into two broad classes:
those acquired directly from the host, and those that appear to
have no relation to host proteins based on sequence similarity,
many members of the latter group are in fact host-protein derived.
Thus, apparently unrelated sequences have often diverged from
host acquired genes, whilst maintaining a conservation of 3-
dimensional structure (Gewurz et al., 2001).
Poxviruses target many fundamental components of the innate
immune response; namely the inﬂammatory response (IFNs, cyto-
kines, chemokines) and apoptosis (death-receptor and Bcl-2 path-
ways). Although many of these immunomodulators have been
identiﬁed based on sequence similarity to cellular products (Jack-
son et al., 2005; Seet et al., 2003), the results achieved through
SPINE2-Complexes have shown how viral proteins with no clear
resemblance to host components at the sequence level have main-
tained a high level of structural conservation (N1, B14 and A52) or
M.W. Bahar et al. / Journal of Structural Biology 175 (2011) 127–134 133have shown distinct folds (A41). For these proteins the structure
has provided a lead for investigating the biological function, how-
ever it is also striking how the original functions of these folds have
not only been maintained or enhanced but have frequently been
diversiﬁed to enrich the viral arsenal against host immune assault.
It is clear from our current knowledge that structural analysis of
further poxviral proteins that have unknown function and no se-
quence similarity to host proteins will reveal many more viral
immunomodulators, further enhancing our understanding of the
host immune system and the viral response, and potentially allow-
ing us to leverage the evolutionary struggle between host and virus
in order to inform the development of new therapeutics for viral
and non-viral disease.Acknowledgments
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